These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39271993)

  • 1. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
    Zhu Y; Xue F
    BMC Cancer; 2024 Sep; 24(1):1145. PubMed ID: 39271993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
    Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
    Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
    Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
    Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
    Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
    Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.
    Wang F; Chuner J; Lei W; Fengqin Y; Zhimin Y; Quanquan S; Tongxin L; Zhenfu F; Yangming J
    Medicine (Baltimore); 2020 Sep; 99(39):e22283. PubMed ID: 32991429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies.
    Chan SK; Chan SY; Tong CC; Lam KO; Kwong DL; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
    Oral Oncol; 2021 Mar; 114():105158. PubMed ID: 33508707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
    BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
    Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
    Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.
    Zheng SH; Liu SR; Wang HB; Wei YH; Li H; Wang GN; Huang ZL; Ding SR; Chen C; Tao YL; Li XH; Glorieux C; Huang P; Wu YF; Xia YF
    JAMA Netw Open; 2021 Dec; 4(12):e2138444. PubMed ID: 34902036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin.
    Zeng Z; Yan RN; Tu L; Wang YY; Chen PR; Luo F; Liu L
    Sci Rep; 2018 Oct; 8(1):15581. PubMed ID: 30348970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
    Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.